Eagle Pharmaceuticals
EGRX
$4.57
Share price
3.63%
Change (1 day)
-84.33%
Change (1 year)
Categories
Eagle Pharmaceuticals (EGRX) - Cash on Hand
Cash on Hand as of June 2023 : $15.35 M
According to Eagle Pharmaceuticals
's latest financial reports the company has $15.35 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Eagle Pharmaceuticals - Cash on Hand chart (from 2013 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $55.32 M | -43.35% |
| 2021-12-31 | $97.65 M | -5.33% |
| 2020-12-31 | $0.10 B | -6.03% |
| 2019-12-31 | $0.10 B | 39.32% |
| 2018-12-31 | $78.79 M | -31.28% |
| 2017-12-31 | $0.11 B | 117.07% |
| 2016-12-31 | $52.82 M | -33.21% |
| 2015-12-31 | $79.08 M | |
| 2014-09-30 | $42.72 M | 308.58% |
| 2013-09-30 | $10.45 M | 59.22% |
| 2012-09-30 | $6.56 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $26.21 B | 170,656.81% | 🇺🇸 USA |
 Novartis NVS | $9.69 B | 63,036.64% | 🇨🇭 Switzerland |
 Eli Lilly LLY | $2.58 B | 16,744.47% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 71,177.84% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $9.67 B | 62,880.33% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $5.17 B | 33,604.31% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $3.22 B | 20,910.81% | 🇮🇱 Israel |